Submissions from 2025
Gabapentinoids confer survival benefit in human glioblastoma, Matthew Hall and Yazmin Odia
A pilot survey into the landscape of neuro-oncology care in the community, Rupesh Kotecha and Yazmin Odia
Submissions from 2024
An Update on H3K27M-altered Diffuse Midline Glioma: Diagnostic and Therapeutic Challenges in Clinical Practice, Eyub Akdemir, Yazmin Odia, Matthew Hall, Minesh Mehta, and Rupesh Kotecha
Comparative evaluation of the diagnostic and prognostic performance of CNSide™ versus standard cytology for leptomeningeal disease, Haley Appel, Muni Rubens, Mukesh Roy, Rupesh Kotecha, Matthew Hall, Minesh Mehta, Zhijian Chen, Manmeet Ahluwalia, and Yazmin Odia
An Overview of the Therapeutic Strategies for Neoplastic Meningitis due to Breast Cancer: When and Why?, Mainak Bardhan, Ahmad Ozair, Reshma Mahtani, Yazmin Odia, and Manmeet Ahluwalia
Comparative evaluation of outcomes amongst different radiosurgery management paradigms for patients with large brain metastasis, Tugce Kutuk, Yanjia Zhang, Eyub Akdemir, Sreenija Yarlagadda, Ranjini Tolakanahalli, Matthew Hall, Alonso La Rosa De Los Rios, D Jay Wieczorek, Cecilia Lee, Haley Appel, Michael McDermott, Yazmin Odia, Manmeet Ahluwalia, Alonso Gutierrez, Minesh Mehta, Rupesh Kotecha, and Robert Press
Initial feasibility cohort of temporally modulated pulsed proton re-irradiation (TMPPR) for recurrent high-grade intracranial malignancies, Alonso LaRosa, Zachary Fellows, Andrew Wroe, Len Coutinho, Eduardo Pons, Nicole McAllister, Ranjini Tolakanahalli, Tugce Kutuk, Matthew Hall, Robert Press, Michael McDermott, Yazmin Odia, Manmeet Ahluwalia, Minesh Mehta, Alonso Gutierrez, and Rupesh Kotecha
Diffuse midline glioma, H3K27-altered: Illuminating the dark side of the moon, Yazmin Odia
Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma, Yazmin Odia, Doured Daghistani, and Matthew Hall
Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort, Yazmin Odia and Matthew Hall
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma, Yazmin Odia and Minesh Mehta
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma, Yazmin Odia and Minesh Mehta
Submissions from 2023
A Randomized Phase 2b Study of Surviving Vaccine Survaxm Plus Adjuvant Temozolomide For Newly-Diagnosed Glioblastoma (SURVIVE), Manmeet Ahluwalia, Yazmin Odia, Ahmad Ozair, and Atulya Khosla
Evaluating the Diagnostic Performance of Leptomeningeal Diagnosis with CNSide™ Compared to Standard Cytology, Haley Appel, Anshul Saxena PhD, Rupesh Kotecha, Alexander Mohler, Matthew Hall, Manmeet Ahluwalia, Minesh Mehta, Yazmin Odia, and Serguei Castaneda
Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations, Sajeel Chowdhary
Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial, Sajeel Chowdhary
Dose-escalated proton therapy with concurrent and adjuvant immunotherapy for chordoma: Early results and toxicities from a single institution case series , Matthew Hall, Yazmin Odia, Minesh Mehta, Muni Rubens, Ranjini Tolakanahalli, Alonso Gutierrez, Keitrina Mair, Katherine Von Werne, and Carlos Rios
Evaluation of an interactive, multi-language, neurocognitive app in CNS radiation oncology, Rupesh Kotecha, Tugce Kutuk, Muni Rubens, Yazmin Odia, Matthew Hall, Michael McDermott, Manmeet Ahluwalia, Minesh Mehta, Suyen Ramos, and Miguel Ramirez Menendez
Key Clinical Principles in the Management of Glioblastoma, Rupesh Kotecha, Yazmin Odia, Atulya Khosla, and Manmeet Ahluwalia
Proton craniospinal irradiation for patients with solid tumor leptomeningeal metastasis: Initial real-world clinical experience, Tugce Kutuk, Haley Appel, Zachary Fellows, Alonso La Rosa de los Rios, Yazmin Odia, Matthew Hall, Manmeet Ahluwalia, Minesh Mehta, Rupesh Kotecha, and Sreenija Yarlagadda
The Initial Clinical Experience with an Interactive, Multi-Language, App-Based Neurocognitive Evaluation Program for Proton Therapy on CNS Malignancies, Tugce Kutuk, Rupesh Kotecha, Yazmin Odia, Matthew Hall, Haley Appel, Miguel Ramirez Menendez, Manmeet Ahluwalia, Minesh Mehta, and Alonso La Rosa de los Rios
Integration of an APP-based Neurocognitive Evaluation Program into Stereotactic Radiosurgery Practice: Outcomes and Patient Survey Analysis from a Prospective Observational Study, Tugce Kutuk, Cecilia Lee, Yazmin Odia, Alonso La Rosa de los Rios, Matthew Hall, Haley Appel, Michael McDermott, Manmeet Ahluwalia, Minesh Mehta, and Rupesh Kotecha
Implementation of an Interactive, Multi-Language, App-Based Neurocognitive Evaluation Program into Routine Stereotactic Radiosurgery Practice, Tugce Kutuk, Yazmin Odia, Matthew Hall, Haley Appel, Miguel Ramirez Menendez, Alexander Mohler, Michael McDermott, Manmeet Ahluwalia, Minesh Mehta, and Rupesh Kotecha
Temporally modulated pulsed proton re-irradiation (TMPPR) for recurrent high-grade gliomas, Alonso La Rosa de los Rios, Alonso Gutierrez, Yazmin Odia, Michael McDermott, Manmeet Ahluwalia, Minesh Mehta, and Rupesh Kotecha
Treatment of glioblastoma using MRIdian® A3i BrainTx™: Imaging and treatment workflow demonstration, Alonso La Rosa De Los Rios, Kathryn Mittauer, Amy Rzepczynski, Michael Chuong, Tugce Kutuk, Nicole McAllister, Matthew Hall, James McCulloch, Diane Alvarez, Roberto Herrera, Alonso Gutierrez, Ranjini Tolakanahalli, Yazmin Odia, Manmeet Ahluwalia, Minesh Mehta, and Rupesh Kotecha
Estimated Prevalence, Tumor Spectrum, and Neurofibromatosis Type 1-Like Phenotype of CDKN2A-Related Melanoma-Astrocytoma Syndrome, Arelis Martir-Negron and Yazmin Odia
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways, Minesh Mehta, Matthew Hall, Doured Daghistani, and Yazmin Odia
DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets, Ahmad Ozair, Atulya Khosla, Rupesh Kotecha, Yazmin Odia, Michael McDermott, and Manmeet Ahluwalia
Submissions from 2022
Change in Hippocampus Volume as a Function of Radiation Dose: Results from a Prospective Trial with Standardized Imaging and Morphometric Evaluation. Change in Hippocampus Volume as a Function of Radiation Dose: Results from a Prospective Trial with Standardized Imaging and Morphometric Evaluation, Matthew Hall, Yazmin Odia, Katherine Von Werne, Alexander Mohler, Rupesh Kotecha, Noah Kalman, Martin Tom, Kevin Abrams, Michael Chuong, Andrew Wroe, Alonso Gutierrez, and Minesh Mehta
Does Hippocampal Atrophy Correlate with Neurocognitive Outcomes One Year Following Radiotherapy? Results from a Prospective Trial, Matthew Hall, Katherine Von Werne, Muni Rubens, Rupesh Kotecha, Alexander Mohler, Yazmin Odia, Noah Kalman, Kevin Abrams, Andrew Wroe, Alonso Gutierrez, Michael Chuong, and Minesh Mehta
Evaluation of the impact of pre-operative stereotactic radiotherapy on the acute changes in histopathologic and immune marker profiles of brain metastases, Rupesh Kotecha, Raees Tonse, Miguel Ramirez Menendez, Zuanel Diaz, Martin Tom, Matthew Hall, Minesh Mehta, Vitaly Siomin, Yazmin Odia, Manmeet Ahluwalia, and Michael McDermott
Pulsed reduced dose rate (PRDR) intensity-modulated radiotherapy for recurrent primary central nervous system malignancies: dosimetric and clinical results, Tugce Kutuk, Nicole McAllister, Matthew Hall, Martin Tom, Haley Appel, Ranjini Tolakanahalli, Alonso Gutierrez, Yazmin Odia, Alexander Mohler, Manmeet Ahluwalia, Minesh Mehta, and Rupesh Kotecha
Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy, Yazmin Odia, Doured Daghistani, Zuanel Diaz, and Matthew Hall
Stereotactic targeted radiation therapy (STaRT) trials for brain neoplasms: A comprehensive review, Yazmin Odia, Alonso Gutierrez, and Rupesh Kotecha
Relationship between insurance status and interhospital transfers among cancer patients in the United States, Muni Rubens, Venkataraghavan Ramamoorthy, Anshul Saxena, Emir Veledar, Peter McGranaghan, Raees Tonse, Michael Chuong, Yazmin Odia, Minesh Mehta, and Rupesh Kotecha
Submissions from 2021
Modified RANO (mRANO), iRANO, and standard RANO response to convection-enhanced delivery of IL4R-targeted immunotoxin MDNA55 in recurrent glioblastoma, Sajeel Chowdhary and Frank Vrionis
Regression of Intracranial Meningiomas Following Treatment with Cabozantinib, Rupesh Kotecha, Raees Tonse, Haley Appel, Yazmin Odia, Guilherme Rabinowits, and Minesh Mehta
Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance, Rupesh Kotecha, Raees Tonse, Muni Rubens, Michael McDermott, Yazmin Odia, Haley Appel, and Minesh Mehta
PARP Inhibitor Tolerability and Impact on Progression-Free Survival in Patients with High-Grade, Ovarian Carcinoma with Brain Metastasis: A Case-Series, Alexander Mohler, Belkys Salinas, Rupesh Kotecha, Karissa Nazur, Yazmin Odia, and Nicholas Lambrou
PARP Inhibitor Tolerability and Impact on Progression-Free Survival in Patients with High-Grade, Ovarian Carcinoma with Brain Metastasis: A Case-Series, Alexander Mohler, Belkys Salinas, Nicholas Lambrou, Karissa Nazur, Yazmin Odia, and Rupesh Kotecha
Contemporary Neuroscience Core Curriculum for Medical Schools, Yazmin Odia
Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors, Yazmin Odia and Bruno Bastos
Single agent activity of ONC201 in non-midline H3 K27M-mutant diffuse gliomas, Yazmin Odia, Matthew Hall, Doured Daghistani, and Minesh Mehta
A Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma, Yazmin Odia and Minesh Mehta
Lumican, Pro-tumorigenic or Anti-tumorigenic: A Conundrum, Muni Rubens, Anshul Saxena, Peter McGranaghan, Yazmin Odia, and Rupesh Kotecha
Hospitalization rates for complications due to systemic therapy in the United States, Anshul Saxena, Muni Rubens, Venkataraghavan Ramamoorthy, Raees Tonse, Emir Veledar, Peter McGranaghan, Michael Chuong, Matthew Hall, Yazmin Odia, Minesh Mehta, and Rupesh Kotecha
Chemotherapy-induced changes in tumor consistency can allow gross total resection of previously unresectable brainstem pilocytic astrocytoma, Vitaly Siomin and Yazmin Odia
Systematic review and meta-analysis of lung cancer brain metastasis and primary tumor receptor expression discordance, Raees Tonse, Muni Rubens, Haley Appel, Martin Tom, Matthew Hall, Yazmin Odia, Michael McDermott, Manmeet Ahluwalia, Minesh Mehta, and Rupesh Kotecha
Systematic review and meta-analysis of PD-L1 expression discordance between primary tumor and lung cancer brain metastasis, Raees Tonse, Muni Rubens, Haley Appel, Martin Tom, Matthew Hall, Yazmin Odia, Michael McDermott, Manmeet Ahluwalia, Minesh Mehta, and Rupesh Kotecha
OTHR-07. Systematic Review and Meta-analysis of Lung Cancer Brain Metastasis and Primary Tumor PD-L1 Expression Discordance, Raees Tonse, Muni Rubens, Haley Appel, Martin Tom, Matthew Hall, Yazmin Odia, Minesh Mehta, Michael McDermott, manmeet Ahluwalia, and Rupesh Kotecha
Factors associated with unplanned readmissions and costs following resection of brain metastases in the United States, Raees Tonse, Muni Rubens, Vitaly Siomin, Michael McDermott, Martin Tom, Matthew Hall, Yazmin Odia, Manmeet Ahluwalia, Minesh Mehta, and Rupesh Kotecha
Submissions from 2020
Pulsed-reduced dose rate (PRDR) radiotherapy for recurrent primary central nervous system malignancies: dosimetric and clinical results, Tugce Kutuk, Alexander Mohler, Nicole McAllister, Matthew Hall, Martin Tom, Haley Appel, Ranjini Tolakanahalli, Alonso Gutierrez, Yazmin Odia, Manmeet Ahluwalia, Minesh Mehta, and Rupesh Kotecha
CTIM-15. PRELIMINARY RESULTS OF A PHASE II STUDY OF NIVOLUMAB WITH HYPOFRACTIONATED RE-RADIATION AND BEVACIZUMAB FOR RECURRENT MGMT METHYLATED GLIOBLASTOMA, Minesh Mehta, Rupesh Kotecha, and Yazmin Odia
CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA, Minesh Mehta, Yazmin Odia, Matthew Hall, and Doured Daghistani
HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA, Minesh Mehta, Yazmin Odia, Matthew Hall, and Doured Daghistani
DIPG-52. PHASE I CLINICAL TRIAL OF ONC201 IN PEDIATRIC H3 K27M-MUTANT GLIOMA OR NEWLY DIAGNOSED DIPG, Yazmin Odia, Matthew Hall, and Doured Daghistani
ONC201 in previously irradiated pediatric H3 K27M-mutant glioma or newly diagnosed DIPG, Yazmin Odia, Matthew Hall, and Doured Daghistani
Biological activity of weekly ONC201 in adult recurrent glioblastoma patients, Yazmin Odia and Minesh Mehta
Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma, Yazmin Odia and Minesh Mehta
Early imaging marker of progressing glioblastoma: a window of opportunity, Yazmin Odia and Minesh Mehta
Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma, Yazmin Odia and Minesh Mehta
RADT-31. PATTERNS OF CARE IN THE USE OF ADJUVANT RADIOTHERAPY AND CHEMOTHERAPY IN LOW GRADE GLIOMA PATIENTS IN THE UNITED STATES FROM 2010-2016, Warren Rehrer, Yazmin Odia, Muni Rubens, Noah Kalman, Michael Chuong, Rupesh Kotecha, Minesh Mehta, and Matthew Hall
The Use of Adjuvant Radiotherapy and Chemotherapy in Low Grade Glioma Patients in the United States from 2010-2016, Warren Rehrer, Muni Rubens, Katherine Von Werne, Yazmin Odia, Michael Chuong, Rupesh Kotecha, Minesh Mehta, and Matthew Hall
Recent Health Care Expenditure Trends Among Adult Cancer Survivors in United States, 2009-2016, Muni Rubens, Anshul Saxena, Sankalp Das, Chintan Bhatt, Emir Veledar, Peter McGranaghan, Ana Viamonte Ros, Yuliya Linhares, Yazmin Odia, Michael Chuong, Rupesh Kotecha, and Minesh Mehta
Submissions from 2019
EBV-positive primary CNS lymphoma restricted to the conus medullaris in an immunocompetent host, Matthew Hall, Lyle Feinstein, Sergio Gonzalez-Arias, and Yazmin Odia
First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report, Matthew Hall, Yazmin Odia, Doured Daghistani, and Minesh Mehta
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201, Matthew Hall, Yazmin Odia, and Minesh Mehta
Core curriculum guidelines for a required clinical neurology experience, Yazmin Odia
Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations, Yazmin Odia
Submissions from 2017
Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options, Yazmin Odia
BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors, Ashley Roque and Yazmin Odia
Submissions from 2016
Gangliocytomas and Gangliogliomas: Review of Clinical, Pathologic and Genetic Features, Yazmin Odia
Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy, Yazmin Odia